The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents.
Tim KeulerCarina LemkePaul W ElsinghorstIsabel IriepaMourad ChiouaMaría Angeles Martínez-GrauChristopher D BeadleTatiana VetmanFrancisco López-MuñozTimo WilleUlrike BartzWinnie Deuther-ConradJosé Marco-ContellesMichael GütschowPublished in: ACS pharmacology & translational science (2022)
The multifactorial nature of Alzheimer's disease necessitates the development of agents able to interfere with different relevant targets. A series of 22 tailored chromanones was conceptualized, synthesized, and subjected to biological evaluation. We identified one representative bearing a linker-connected azepane moiety (compound 19 ) with balanced pharmacological properties. Compound 19 exhibited inhibitory activities against human acetyl-, butyrylcholinesterase and monoamine oxidase-B, as well as high affinity to both the σ 1 and σ 2 receptors. Our study provides a framework for the development of further chromanone-based multineurotarget agents.